Dermatophytic Onychomycosis Treatment Market - by Therapy Type (Systemic Therapy, Topical Therapy, and Device-based Therapy), by End User (Hospitals, Dermatology Clinics, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

  • Published On : Aug 2018 |
  • Pages : 140 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Dermatophytic Onychomycosis Treatment Market

Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.

Major symptoms of dermatophytic onychomycosis include thickening and whitening of nails. Moreover, the nails become brittle and appear white as the infection progresses. People suffering from diabetes, peripheral vascular disease, HIV, immune suppression, obesity, and geriatric population are at increased risk of this common fungal infection. Dermatophytic onychomycosis could be treated with either topical preparations or oral antifungal agents based on the severity of infection. The treatment often lasts for an average period of six months. In recent past, advancement in therapy with the introduction of effective topical and oral products has controlled the rapid spread of dermatophytic onychomycosis.

The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026).

Figure 1. Global Dermatophytic Onychomycosis Treatment Market Value (US$ Mn), by Region, 2017

Dermatophytic Onychomycosis Treatment  | Coherent Market Insights

Source – Coherent Market Insights Report

Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market

Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.

However, several factors deter growth for the dermatophytic onychomycosis treatment market. For instance, treatment of dermatophytic onychomycosis on an average lasts for 5-6 months and with such long term course, patient’s compliance is a critical problem with dose fatigue and adverse effects on body parts such as liver, kidney, and heart (hepatic, renal impairment). 

Moreover, high risk of disease recurrence negatively impacts the dermatophytic onychomycosis treatment market growth due to unwillingness of patients to follow treatment that lasts long. Furthermore, several patients often neglect this fungal infection which results in large number of population devoid of therapy access, which in turn hampers the market growth.

Figure 2. Global Dermatophytic Onychomycosis Treatment Market Share, By Therapy Type

Dermatophytic Onychomycosis Treatment  | Coherent Market Insights

Source – Coherent Market Insights Report

Development of new therapies that aid in treatment of dermatophytic onychomycosis is expected to drive growth of the dermatophytic onychomycosis treatment market over the forecast period

Introduction of new drug candidates and adoption of new treatment approaches is a major factor contributing to the dermatophytic onychomycosis treatment market growth. For instance, in 2014, the U.S. Food and Drug Administration (FDA) approved two new topical antifungal drugs—efinaconazole and tavaborole— for the treatment of dermatophytic onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole is the first approved topical triazole antifungal agent and tavaborole is the first approved oxobarole antifungal agent for this indication. These agents offer short treatment courses, high cure rates, and few relapse cases.

Moreover, increasing preference of laser-based therapy for external treatment of dermatophytic onychomycosis is expected to propel the market growth. The treatment is preferred by patients with drug adversity aroused from continuous use of systemic antifungal agents. Furthermore, Ionophresis and photodynamic therapy which are emerging approaches to treat dermatophytic onychomycosis are witnessing significant growth, owing to efforts going on establishing clinical evidence for them.

Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc.,  GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc.,  Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and  Merz Pharma.

Nail onychomycosis or fungus infection is caused by a fungus called Trichophyton rubrum and Trichophyton mentagrophytes. However, few cases may also be caused by yeasts and molds. Fungi grow and spread due to conditions of warmth and moisture. The infection begins as a white or yellow spot under the tip of the nail and as it spreads deeper into the nail, it causes potentially painful nail discoloration, thickening, and development of crumbling edges. Onychomycosis commonly affects toenails than in fingernails, as toenails are often confined in a dark, warm, moist environment inside shoes where fungi can thrive. Old age people are more likely to be affected by the disease due to suppressed nail growth and immunity, and other complications.

Market Dynamics

Major driver for growth of the dermatophytic onychomycosis treatment market is high prevalence of dermatophytic onychomycosis worldwide. According to a study published in the Journal of the European Academy of Dermatology and Venereology in 2013, the mean prevalence of dermatophytic onychomycosis in Europe and North America was 4.3% in the population-based studies and 8.9% in the hospital-based studies. According to the Centre for Disease Control and Prevention statistics in 2017, around 23 million people in the U.S. are affected by this disease each year.

Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.

Key features of the study:

  • This report provides in-depth analysis of dermatophytic onychomycosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc,  GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc.,  Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and  Merz Pharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the dermatophytic onychomycosis treatment market

Detailed Segmentation:

  • Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type:
    • Systemic Therapy
    • Topical Therapy
    • Device-based Therapy
  • Global Dermatophytic Onychomycosis Treatment Market, By End User:
    • Hospitals
    • Dermatology Clinics
    • Retail Pharmacies
    • Others
  • Global Dermatophytic Onychomycosis Treatment Market, By Geography:
    • North America
      • By Therapy Type
        • Systemic Therapy
        • Topical Therapy
        • Device-based Therapy
      • By End Users
        • Hospitals
        • Dermatology Clinics
        • Retail Pharmacies
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Therapy Type
        • Systemic Therapy
        • Topical Therapy
        • Device-based Therapy
      • By End Users
        • Hospitals
        • Dermatology Clinics
        • Retail Pharmacies
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Therapy Type
        • Systemic Therapy
        • Topical Therapy
        • Device-based Therapy
      • By End Users
        • Hospitals
        • Dermatology Clinics
        • Retail Pharmacies
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Therapy Type
        • Systemic Therapy
        • Topical Therapy
        • Device-based Therapy
      • By End Users
        • Hospitals
        • Dermatology Clinics
        • Retail Pharmacies
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Therapy Type
        • Systemic Therapy
        • Topical Therapy
        • Device-based Therapy
      • By End Users
        • Hospitals
        • Dermatology Clinics
        • Retail Pharmacies
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Therapy Type
        • Systemic Therapy
        • Topical Therapy
        • Device-based Therapy
      • By End Users
        • Hospitals
        • Dermatology Clinics
        • Retail Pharmacies
        • Others
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bausch Health Companies  *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Market Strategies
    • Novartis AG
    • Johnson and Johnson
    • Galderma S.A.,
    • Anacor Pharmaceuticals
    • Celtic Pharmaceuticals
    • GlaxoSmithKline
    • Pfizer Inc
    • Moberg Pharma AB

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Therapy Type
      • Market Devices, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • New Product Launches
    • Mergers and Acquisitions
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Pipeline Analysis
  4. Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Systemic Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Topical Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Device-based Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  5. Global Dermatophytic Onychomycosis Treatment Market, By End User, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Dermatology Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Others 
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  6. Global Dermatophytic Onychomycosis Treatment Market, By Region, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 – 2026
    • North America
      • Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By End User, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By End User, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By End User, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • Germany
        • U.K.
        • France        
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By End User, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018-2026, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By End User, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018-2026, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By End User, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018-2026, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Market Share Analysis
    • Company Profiles
      • Bausch Health Companies*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Galderma SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Celtic Pharma
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Anacor pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Topica Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 19 market data tables and 23 figures on “Dermatophytic Onychomycosis Treatment Market” - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.